Back to Search Start Over

Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia

Authors :
Supriya G. Mohile
Heidi D. Klepin
Wendy Stock
Michael W. Becker
Sindhuja Kadambi
Jason H. Mendler
Jane L. Liesveld
Kah Poh Loh
Paul R. Duberstein
Marsha N. Wittink
Navneet S. Majhail
Kristen M. O'Dwyer
Tanya M. Wildes
Colin McHugh
Source :
Blood. 132:2246-2246
Publication Year :
2018
Publisher :
American Society of Hematology, 2018.

Abstract

Introduction: Despite data supporting the safety and efficacy of treatment for many older adults with AML, Methods: We conducted semi-structured interviews with 13 community oncologists (9 states) and 9 patients aged ≥60 with AML at any stage of treatment to elicit potential factors that influence treatment decisions. Patients were recruited from the outpatient clinics in a single institution and oncologists were recruited via email using purposive samples (patients: based on treatment received and stage of treatment; oncologists: based on practice location). Interviews were audio-recorded and transcribed. We utilized directed content analysis and adapted the decision-making model introduced by Zafar et al. to serve as a framework for categorizing the factors at various levels. A codebook was provisionally developed. Using Atlas.ti, two investigators independently coded the initial transcripts and resolved any discrepancies through an iterative process. The coding scheme was subsequently applied to the rest of the transcripts by one coder. Results: Median age of the oncologists was 37 years (range 34-64); 62% were females, 92% were white, 38% had practiced more than 15 years, and 92% reported seeing Conclusions: Treatment decision-making for older patients with AML is complex and influenced by many factors at the patient, disease/treatment, physician, and organizational levels. Despite studies supporting the utility of objective fitness assessments, these were not commonly performed in the community due to several barriers. Our framework will be useful to guide a larger study to assess real-life treatment decision-making in the community settings. We also identified several barriers raised by community oncologists that could be targeted to allow incorporation of objective fitness assessments. Figure 1. Figure 1. Disclosures Liesveld: Onconova: Other: DSMB; Abbvie: Honoraria. Stock:Jazz Pharmaceuticals: Consultancy. Majhail:Anthem, Inc.: Consultancy; Atara: Honoraria; Incyte: Honoraria. Wildes:Janssen: Research Funding. Klepin:Genentech Inc: Consultancy.

Details

ISSN :
15280020 and 00064971
Volume :
132
Database :
OpenAIRE
Journal :
Blood
Accession number :
edsair.doi...........5b325eba2d795ff292d74ffbea929eb6